Go or no go? FDA firsts for Imfinzi, Enhertu and roflumilast
Assets in oncology and psoriasis are set for upcoming Pdufa decisions.
Aclaris’s second crack at a topical Jak
But, with Incyte close to market and several big players moving forward, Aclaris’s project will need to stand out from the pack.
First-quarter catalysts for the smaller players
Important data releases are on the cards for Rhythm, Wave and Supernus, among others.
